AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BSX · NYSE · Medical - Devices

Boston Scientific

Builds minimally invasive devices for cardiovascular, endoscopic, urological and neuromodulation procedures.

$46.85

After-hours close+0.02 (+0.03%)

At close$46.84(+0.35%)

Something off on this page? Send us feedback.

Profile

Boston Scientific CorporationBSXHealth Care

Develops minimally invasive devices for cardiovascular, endoscopic, urological and neurological procedures, earning revenue from sales to hospitals, physicians and other care providers worldwide. Cardiovascular accounts for most sales, led by platforms spanning electrophysiology, left-atrial-appendage closure and interventional cardiology.

Develops and sells minimally invasive medical devices used in cardiovascular and MedSurg procedures. The Cardiovascular segment spans electrophysiology, WATCHMAN left-atrial-appendage closure, cardiac rhythm management, interventional cardiology and vascular therapies, and interventional oncology and embolization. MedSurg covers endoscopy, urology and neuromodulation.

Growth is built around new-product launches and acquired platforms, with FARAPULSE pulsed-field ablation a recent driver. Hospitals, physicians and other healthcare providers purchase the devices, while the United States supplies most sales and international markets provide the balance.

Commercialization depends on clinical evidence, regulatory clearance and country-specific reimbursement. Manufacturing also relies on some custom or single-source components, and medical-device rules govern product design, production, labeling, distribution and post-market monitoring.

Company facts

CEOMichael F. Mahoney

ListedMay 19, 1992

ExchangeNYSE

HeadquartersMarlborough, MA

CountryUnited States

Employees59,000

CIK0000885725

ISINUS1011371077

Key statistics

Market cap$69.62B

EPS (ttm)$2.46

P/E (ttm)19.04

ROE14.9%

P/B2.78

P/S3.32

Dividend yield—

Beta0.20vs XLV 0.62

Year to date −50.5% · Average volume (30d) 20.2M

Analysts

Price target, next 12 months$63.50+35.6%Median of 44 analysts · vs the Aug 28 close

ConsensusBuy38 of 44 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $46.84

High$100.00+113.5%

Median$63.50+35.6%

Low$50.00+6.7%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
Jul 31, 2026	Argus Research	Downgrade	Buy	Hold
Jul 30, 2026	RBC Capital	Reiterate		Outperform	$85	$70
Jul 30, 2026	UBS	Reiterate		Buy	$74	$67
Jul 30, 2026	Deutsche Bank	Reiterate		Buy	$78	$60
Jul 30, 2026	Robert W. Baird	Target			$70	$56

Earnings

EPS

Estimate$0.80

ReportedDue Oct 28, 2026

Revenue

Estimate$5.26B

ReportedDue Oct 28, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Jul 29, 2026Q2 FY26	$0.84	$0.86	+3.0%	$5.38B	$5.44B	+1.2%	−0.04%
Apr 22, 2026Q1 FY26	$0.79	$0.80	+1.5%	$5.17B	$5.20B	+0.6%	+1.26%
Feb 4, 2026Q4 FY25	$0.78	$0.80	+2.4%	$5.28B	$5.29B	+0.1%	+2.83%
Oct 22, 2025Q3 FY25	$0.71	$0.75	+5.0%	$4.97B	$5.07B	+1.9%	−1.41%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$4.66B	$5.06B	$5.07B	$5.29B	$5.20B	$5.44B
Gross profit	$2.95B	$3.42B	$3.54B	$3.94B	$3.61B	$3.85B
Operating income	$896.0M	$819.0M	$1.05B	$1.21B	$1.07B	$1.18B
Net income	$674.0M	$793.0M	$755.0M	$668.0M	$1.34B	$907.0M
Diluted EPS	$0.45	$0.53	$0.50	$0.45	$0.90	$0.61
Gross margin	63.3%	67.7%	69.9%	74.5%	69.4%	70.7%
Operating margin	19.2%	16.2%	20.7%	22.8%	20.6%	21.6%

Fiscal years (4-quarter sums)FY21 $11.89B · FY22 $12.68B · FY23 $14.24B · FY24 $16.75B · FY25 $20.08B

Revenue by product · Q2 FY26

Cardiovascular$3.62B · 67%

MedSurg$1.82B · 33%

Revenue by geography · Q2 FY26

Non-US$2.02B · 77%

United States$606.0M · 23%

Balance sheet, Jun 30, 2026Cash & short-term investments $539.0M · Total debt $12.62B · Total assets $45.22B · Shareholders' equity $24.93B

Dividends

No dividends on record.

Ownership

Institutions 96.54%1.43B sharesInsiders 0.16%2.33M sharesOther 3.30%49.15M shares

Shares outstanding 1.49B · Float 1.48B · 99.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
BlackRock, Inc.	129.68M	8.72%	13F	Aug 7, 2026
Vanguard Capital Management LLC	97.09M	6.53%	13F	Aug 13, 2026
State Street Corp	70.11M	4.72%	13F	Aug 7, 2026
Primecap Management Co/CA/	50.52M	3.40%	13F	Aug 14, 2026
FMR LLC	45.70M	3.07%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 25, 2026	Susan E. Morano	director	+2,040	$49.22
Aug 5, 2026	David C. Habiger	director	+2,100	$47.59
Aug 3, 2026	Michael F. Mahoney	director, officer: Chairman, President & CEO	+186,240	$48.33
Aug 3, 2026	David C. Habiger	director	+1,042	$48.07
Aug 4, 2026	David C. Habiger	director	+140	$48.59